Annexon, Inc.

NASDAQ:ANNX

6.93 (USD) • At close September 18, 2024
Bedrijfsnaam Annexon, Inc.
Symbool ANNX
Munteenheid USD
Prijs 6.93
Beurswaarde 732,182,220
Dividendpercentage 0%
52-weken bereik 1.57 - 8.4
Industrie Biotechnology
Sector Healthcare
CEO Mr. Douglas Love Esq., J.D.
Website https://www.annexonbio.com

An error occurred while fetching data.

Over Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which

Vergelijkbare Aandelen

UroGen Pharma Ltd. logo

UroGen Pharma Ltd.

URGN

13.1 USD

CVRx, Inc. logo

CVRx, Inc.

CVRX

8.69 USD

Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc.

HOWL

2.22 USD

Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc.

JSPR

22.74 USD

Checkpoint Therapeutics, Inc. logo

Checkpoint Therapeutics, Inc.

CKPT

2.46 USD

ChromaDex Corporation logo

ChromaDex Corporation

CDXC

3.55 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)